Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global dermatitis drugs market was valued at US$ 5.8 billion in 2021 and is expected to register a revenue CAGR of 14.60% to reach US$ 19.77 billion by 2030.

Dermatitis Drugs Market Fundamentals

Dermatitis refers to a typical skin irritation caused due to fungal and viral infections. Symptoms of dermatitis include dry or itchy skin and a rash. The skin could also blister, leak, crust, or flake. The immune system of an individual can sometimes react strongly to dermatitis by responding to allergens that seem insignificant in atopic dermatitis. The prevalence of atopic dermatitis has increased in the middle-aged patient group. It is more prevalent in males with age 75 and above. The severity and activity of atopic dermatitis in older individuals is greater than in children aged 0-17 and adults aged 18-74. Immunosuppressant drugs, such as cyclosporine, azathioprine, methotrexate, and mycophenolate mofetil, are frequently prescribed drugs for atopic dermatitis.

[875904]

Dermatitis Drugs Market Dynamics

The global dermatitis drugs market is expected to register high revenue growth during the forecast period, due to increase in dermatitis prevalence, which is resulting into a rise in the demand for atopic dermatitis treatment solutions. Furthermore, the proliferation of patient communities and support groups and improving awareness about the disorder are also driving demand for dermatitis drugs.

Due to increase in the adoption of Interleukin -4 inhibitors, such as dipilumab, which is marketed under the brand names dupixent by Sanofi and Regeneron Pharmaceuticals, and Eucrisa by Ancor Pharmaceuticals, there has been a rise in the R&D activities to develop novel drugs. This factor is driving revenue growth in the global dermatitis drugs market.

However, stringent government regulations and limited pipelines are major restraints to revenue growth in the global market.

Dermatitis Drugs Market Ecosystem

The global dermatitis drugs market is analyzed based on four parameters: drug class, disease type, distribution channel, and region. 

Global Dermatitis Drugs Market by Drug Class

[298450]

Based on the drug class, the global dermatitis drugs market is segmented into biologics, PDE4 inhibitors, corticosteroids, and calcineurin inhibitors. 

The corticosteroids segment accounts for the highest revenue share of the dermatitis drugs market. The actions of hormones can be imitated with corticosteroids. In addition to decreasing inflammation, they can reduce immune system hyperactivity, which can aid in vasoconstriction. 

Medications derived from animal or human proteins are known as biologics. Biologics are produced to specifically target the biological processes that result in the inflammation of skin and other organs. The market for atopic dermatitis is rising due to the development of efficient medications, prevalence of the condition, and availability of improved disease diagnostics.

Global Dermatitis Drugs Market by Disease Type

Based on the disease type, the global dermatitis drugs market is segmented into atopic dermatitis and contact dermatitis. 

The atopic dermatitis segment is expected to continue its domination in the dermatitis drugs market during the forecast period. This can be ascribed to rise in the prevalence of atopic dermatitis, increase in the disease awareness, and availability of improved diagnosis techniques. As reported in the Acta Derm Venereologica Journal, the prevalence of atopic dermatitis in adults was 17.1% in Europe in 2020, which was further increased in children. Furthermore, rise in the pipeline products for atopic dermatitis treatment is expected to drive revenue growth in the segment. According to JAAD International, up to 2.4% of people worldwide are affected with atopic dermatitis (AD). Therefore, a high patient pool and higher treatment requirements for atopic dermatitis contribute to the dominant revenue share of the atopic dermatitis segment in the dermatitis drugs market. 

On the other hand, the market observed high demand for specialized creams and ointments during the COVID-19 pandemic. This can be attributed to surge in cases of contact dermatitis during the pandemic. The incidences of hand eczema had increased during this period due to surge in the practice of frequent hand washing among people to avoid the coronavirus infection.

Global Dermatitis Drugs Market by Distribution Channel

Based on the distribution channel, the dermatitis drugs market is segmented into hospitals, aesthetic clinics, and pharmacies. 

The pharmacies segment is expected to continue to lead the global dermatitis drugs market during the forecast period. This is attributed to increase in the availability of topical over-the-counter drugs for the treatment of both atopic dermatitis and contact dermatitis. The position of pharmacies is further strengthened in the Asia Pacific market, as the demand for generic medications is high in the region. Furthermore, the demand for biologics is also gradually rising in the Asia Pacific market, with growing availability in pharmacy sales channels. 

Global Dermatitis Drugs Market by Region 

Based on the region, the global dermatitis drugs market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). 

North America dominates the market due to high prevalence of dermatitis, increase in the disease awareness, and presence of several key market players in the region. 

The Europe dermatitis drugs market is growing at significant revenue CAGR due to increased healthcare expenses, availability of robust reimbursement policies, and high R&D associated with the disease. 

The dermatitis drugs market in Asia Pacific is expected to register high revenue growth during the forecast period due to increased healthcare expenditure, growing disposable income, increasing health awareness, and consistent growth in diagnosis rates in the region.

Dermatitis Drugs Market Competitive Landscape

The prominent players operating in the global dermatitis drugs market are:

• Bayer AG
• LEO Pharma A/S
• Pfizer, Inc. 
• Sanofi SA
• Mylan N.V. 
• Allergan, Inc.
• Anacor Pharmaceuticals, Inc. 
• Regeneron Pharmaceuticals, Inc. 
• Bausch Health Companies, Inc. 
• Teva Pharmaceuticals Industries Ltd. 

Dermatitis Drugs Market Strategic Development/s

• In September 2021, The Opzelura (ruxolitinib) ointment was approved by the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate atopic dermatitis in patients with 12 years and above.

Frequently Asked Questions About This Report